About CraniUS
CraniUS is a company based in Baltimore (United States) founded in 2021 by Chad Gordon. CraniUS has raised $39.5 million across 4 funding rounds from investors including Maryland.gov, Mumbai Angels and Lumis Partners. CraniUS offers products and services including NeuroPASS. CraniUS operates in a competitive market with competitors including Impel NeuroPharma, Cognos Therapeutics, Cordance Medical, PassPort Technologies and Bionxt, among others.
- Headquarter Baltimore, United States
- Founders Chad Gordon
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$39.5 M (USD)
in 4 rounds
-
Latest Funding Round
$19 M (USD), Series B
Jan 28, 2026
-
Investors
Maryland.gov
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CraniUS
CraniUS offers a comprehensive portfolio of products and services, including NeuroPASS.
Skull-implantable device for targeted brain disease treatment and drug administration.
People of CraniUS
Unlock access to complete
Operations Team
1 people
Leadership Team
1 people
Product Management Team
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of CraniUS
CraniUS has successfully raised a total of $39.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $19 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $19.0M
-
First Round
First Round
(04 Aug 2021)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series B - CraniUS | Valuation |
investors |
|
| Jun, 2024 | Amount | Grant - CraniUS | Valuation |
investors |
|
| Sep, 2022 | Amount | Series A - CraniUS | Valuation |
investors |
|
Investors in CraniUS
CraniUS has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Maryland.gov, Mumbai Angels and Lumis Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture investments are facilitated by Mumbai Angels network.
|
Founded Year | Domain | Location | |
|
Investment in alternative assets, businesses, and funds in India.
|
Founded Year | Domain | Location | |
|
Access to government programs and development services is facilitated.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CraniUS
Financial Statements - CraniUS
Cranius Comparisons
Competitors of CraniUS
CraniUS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, Cognos Therapeutics, Cordance Medical, PassPort Technologies and Bionxt, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Cognos Therapeutics is focused on innovative neurological and oncological treatments.
|
|
| domain | founded_year | HQ Location |
Non-invasive ultrasound device for blood-brain barrier is developed.
|
|
| domain | founded_year | HQ Location |
Transdermal drug delivery systems are developed using microporation technology.
|
|
| domain | founded_year | HQ Location |
Drug formulations and delivery systems for diseases are developed.
|
Frequently Asked Questions about CraniUS
CraniUS was founded in 2021.
CraniUS is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Michael Maglin is the current CEO of CraniUS.
CraniUS is a funded company, having raised a total of $39.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Aug 04, 2021.
CraniUS was founded in 2021 in Baltimore, United States, as a medical technology company. Implantable devices are developed by the company for brain tumor treatment and to address disorders such as Alzheimers and Parkinsons. The flagship product, NeuroPASS, is designed to deliver medication directly to the brain, bypassing the blood-brain barrier with controlled flow rates. Operations focus on innovative drug delivery solutions within the neurotherapeutics sector.
CraniUS's top competitors include Impel NeuroPharma, Cognos Therapeutics and Cordance Medical.
CraniUS offers NeuroPASS.
CraniUS has 3 investors. Key investors include Maryland.gov, Mumbai Angels, and Lumis Partners.